HM
HealthCor Management Portfolio holdings
AUM
$109M
This Quarter Return
+23.75%
1 Year Return
+11.46%
3 Year Return
+50.01%
5 Year Return
+144.68%
10 Year Return
–
AUM
$109M
AUM Growth
+$109M
(-86%)
Cap. Flow
-$719M
Cap. Flow
% of AUM
-658.8%
Top 10 Holdings %
Top 10 Hldgs %
91.26%
Holding
65
New
6
Increased
2
Reduced
11
Closed
43
Top Buys
| 1 |
DexCom
DXCM
|
$7.69M |
| 2 |
Acrivon Therapeutics
ACRV
|
$3.27M |
| 3 |
CONMED
CNMD
|
$2.44M |
| 4 |
Intuitive Surgical
ISRG
|
$1.53M |
| 5 |
Penumbra
PEN
|
$1.11M |
Top Sells
| 1 |
AbbVie
ABBV
|
$41.6M |
| 2 |
Agilent Technologies
A
|
$41.1M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
$40.5M |
| 4 |
Boston Scientific
BSX
|
$37.1M |
| 5 |
Eli Lilly
LLY
|
$33.4M |
Sector Composition
| 1 | Healthcare | 99.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AFMD
26
DELISTED
Affimed
AFMD
| – | – | -1,721,925 | Closed | -$3.55M |
|
27
Amgen
AMGN
$155B
| – | – | -75,370 | Closed | -$17M |
|
28
Becton Dickinson
BDX
$55.3B
| – | – | -62,930 | Closed | -$14M |
|
29
Biogen
BIIB
$19.4B
| – | – | -69,950 | Closed | -$18.7M |
|
|
BLUE
30
DELISTED
bluebird bio
BLUE
| – | – | -455,000 | Closed | -$2.88M |
|
31
Bristol-Myers Squibb
BMY
$96B
| – | – | -223,150 | Closed | -$15.9M |
|
|
32
Boston Scientific
BSX
$156B
| – | – | -958,600 | Closed | -$37.1M |
|
33
Cigna
CI
$80.3B
| – | – | -76,910 | Closed | -$21.3M |
|
34
Centene
CNC
$14.3B
| – | – | -300,970 | Closed | -$23.4M |
|
35
Cencora
COR
$56.5B
| – | – | -239,150 | Closed | -$32.4M |
|
36
CVS Health
CVS
$92.8B
| – | – | -131,150 | Closed | -$12.5M |
|
37
Danaher
DHR
$147B
| – | – | -117,800 | Closed | -$30.4M |
|
38
Elevance Health
ELV
$71.8B
| – | – | -38,910 | Closed | -$17.7M |
|
39
Hologic
HOLX
$14.9B
| – | – | -137,330 | Closed | -$8.86M |
|
40
Henry Schein
HSIC
$8.44B
| – | – | -248,920 | Closed | -$16.4M |
|
41
Humana
HUM
$36.5B
| – | – | -42,920 | Closed | -$20.8M |
|
|
IMA
42
ImageneBio, Inc. Common Stock
IMA
$150M
| – | – | -220,082 | Closed | -$781K |
|
43
Incyte
INCY
$16.5B
| – | – | -227,851 | Closed | -$15.2M |
|
44
Kezar Life Sciences
KZR
$28.9M
| – | – | -1,607,650 | Closed | -$13.8M |
|
45
LivaNova
LIVN
$3.08B
| – | – | -328,030 | Closed | -$16.7M |
|
|
46
Eli Lilly
LLY
$657B
| – | – | -103,150 | Closed | -$33.4M |
|
47
Leap Therapeutics
LPTX
$12M
| – | – | -1,066,689 | Closed | -$939K |
|
48
McKesson
MCK
$85.4B
| – | – | -35,040 | Closed | -$11.9M |
|
49
Molina Healthcare
MOH
$9.8B
| – | – | -27,540 | Closed | -$9.08M |
|
50
Merus
MRUS
$4.98B
| – | – | -272,890 | Closed | -$5.47M |
|